TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06619990: Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis

Sponsor: Xencor, Inc. · Phase: PHASE1/PHASE2 · Area: IMMUNOLOGY · Target Enrollment: 270 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$2,258,025

Rescue Site Savings

+$1,495,575

Unlock Full NCT06619990 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06619990 Rescue Dossier →